Merck Stock Sees Modest Upside Amid Patent Pressures

Merck & Co., Inc. (MRK), one of the world's leading pharmaceutical giants, has been a standout performer on Wall Street, with its stock surging 58.8% over the past year and gaining 22% year-to-date in 2026.

The company has a market capitalization of roughly $316.95 billion and a robust research pipeline, which has driven its growth and transformed healthcare globally through breakthrough medicines and vaccines.

Despite intensifying competition and the looming loss of Keytruda's patent exclusivity in 2028, Merck's shares have held up relatively well against the broader market.

The company delivered a stronger-than-expected fiscal 2026 second-quarter earnings report on Aug. 4, beating Wall Street's expectations on both revenue and earnings with quarterly revenue of $16.61 billion, up 5% year over year.